Novartis Pulls Galvus From Germany After Failed Price Negotiations
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis has withdrawn its oral anti-diabetic Galvus from the German market after failing to secure a mutually beneficial price with payers. Galvus is the only drug dropped from reimbursement under a since-repealed policy to assess added benefits of brand drugs marketed before 2011.